A PPARγ agonist, activates PPARγ1 and PPARγ2 in reporter assays (EC50s = 30 and 100 nM, respectively), selectively activates chimeras containing the LBDs of PPARγ over PPARα and PPARΔ in a cell-based reporter assay at 10 mM, an inhibitor of ACSL4 (IC50 = 0.5 µM), inhibits RSL3-induced ferroptosis in Pfa1 cells and Pparg KO cells, and increases survival in a Gpx4 KO mouse model of ferroptosis at 0.0125 mg/ml in the drinking water, decreases HbA1c and fasting blood glucose levels in a rat model of type 2 diabetes induced by STZ and a high-carbohydrate and high-fat diet at 4 mg/kg
